Avatrombopag vs. Placebo for CIT in GI Malignancies
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus
placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with
gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy.
The names of the study drugs involved in this study are:
- Avatrombopag (a thrombopoietin receptor agonist)
- Matching placebo